Pristautz H, Stradner F
Wien Med Wochenschr. 1986 Sep 15;136(17):443-8.
In a single-blind prospective study, patients with hyperlipoproteinemias of the types II a, II b or IV were examined for changes of their serum lipid levels under the treatment with 300 mg celiprolol or 200 mg metoprolol, respectively, for a period of 4 weeks. Celiprolol led to a reduction of serum triglycerides, while the total cholesterol level remained practically unchanged; the HDL-cholesterol level rose from an average of 41.7 to 53.9 mg/dl (p less than or equal to 0.05). There was a slight increase of the LDL-cholesterol level and a significant decrease of the quotients between LDL- and HDL-cholesterol and between total cholesterol and HDL-cholesterol. Metoprolol caused a slight increase of the serum triglycerides, the total cholesterol level remained unchanged, while the HDL-cholesterol level slightly increased from 56.7 to 59.3 mg/dl. The level of LDL-cholesterol and the quotient between LDL-cholesterol and HDL-cholesterol decreased slightly. On the contrary, the quotient between total cholesterol and HDL-cholesterol remained practically unchanged. Celiprolol had a favourable influence on the serum lipid pattern, as far as the atherogenic risk is concerned.
在一项单盲前瞻性研究中,对II a型、II b型或IV型高脂血症患者分别使用300毫克塞利洛尔或200毫克美托洛尔进行为期4周的治疗,并检测其血脂水平的变化。塞利洛尔可使血清甘油三酯降低,而总胆固醇水平基本保持不变;高密度脂蛋白胆固醇水平从平均41.7毫克/分升降至53.9毫克/分升(p≤0.05)。低密度脂蛋白胆固醇水平略有升高,低密度脂蛋白与高密度脂蛋白胆固醇以及总胆固醇与高密度脂蛋白胆固醇的比值显著降低。美托洛尔使血清甘油三酯略有升高,总胆固醇水平不变,而高密度脂蛋白胆固醇水平从56.7毫克/分升略有升至59.3毫克/分升。低密度脂蛋白胆固醇水平以及低密度脂蛋白与高密度脂蛋白胆固醇的比值略有下降。相反,总胆固醇与高密度脂蛋白胆固醇的比值基本保持不变。就动脉粥样硬化风险而言,塞利洛尔对血脂模式有有利影响。